Clinical Research Details Clinical Research Effects of NNC0194-0499, cagrilintide, and semaglutide alone or in combinations on liver damage and alcohol use in people with alcohol-related liver disease Study Description We are doing this study to look at the effects of NNC0194-0499 (alone and in fixed-dose combination with semaglutide), cagrilintide (alone and in fixed-dose combination with semaglutide called CagriSema) and semaglutide (alone), on liver damage and alcohol use in people with Alcoholic Liver Disease. The study will include people with history of alcohol overuse and scar tissue build up in the liver. The study will last about 39 weeks. Inclusion/Exclusion Criteria Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period. Women who are able to become pregnant must use highly effective birth control throughout the study and will be counselled on the use of birth control. You cannot take part if you currently have infectious hepatitis or HIV. Open Enrollment Contact Name: Kelly JackmanContact Phone: (904) 633-0070Contact Email: kelly.jackman@jax.ufl.edu Investigators Neha Agrawal, M.B.B.S. (M.D.) Medicine